dipyridamole has been researched along with Stroke in 263 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 9.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 9.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 9.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| " We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients." | 9.15 | Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. ( Eisert, C; Fong, A; Hanley, D; Sani, Y; Schevchuck, A; Serebruany, V, 2011) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 9.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 9.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "Extended release dipyridamole (ERD) is widely used in patients after ischaemic stroke; however, the ability of this antithrombotic agent to be stored in different blood cells has never been explored in post-stroke patients." | 9.14 | Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. ( Atar, OD; Booze, C; Eisert, C; Hanley, D; Sabaeva, E; Serebruany, V, 2009) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 9.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "The combination of low-dose aspirin and dipyridamole is more effective than aspirin alone in reducing the risk of recurrent stroke and other major cardiovascular events in patients with a recent transient ischemic attack or minor stroke." | 9.14 | Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke. ( Algra, A; Dippel, DW; Halkes, P; Kappelle, LJ; Koudstaal, PJ; Maasland, L, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day." | 9.13 | Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 9.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "In the European Stroke Prevention Study (ESPS 2), oral administration of a fixed combination of 200 mg extended-release dipyridamole and 25 mg aspirin (twice daily) after ischemic stroke or transient ischemic attack, significantly reduced the risk of stroke compared to placebo as well as compared to aspirin or dipyridamole alone." | 9.12 | Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. ( Buell, U; Koch, KC; Noth, J; Nowak, B; Schaefer, WM; Weiss, PH, 2006) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 9.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 9.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months." | 9.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| "In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial." | 9.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "30-day survivors of ischaemic stroke treated with low dose aspirin, modified-release dipyridamole; the coformulation of low dose aspirin plus modified-release dipyridamole, or no antiplatelet therapy." | 9.09 | Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. ( Chambers, M; Gladman, J; Hutton, J, 1999) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 8.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| "To identify confounding factors that may explain the incoherence between direct and indirect evidence in a published analysis comparing extended-release dipyridamole (ERDP) plus aspirin to clopidogrel for the reduction of stroke." | 8.88 | Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. ( Dewilde, S; Hawkins, N, 2012) |
| "Oral antiplatelet drugs, including aspirin, clopidogrel and extended-release dipyridamole, are widely prescribed for the secondary prevention of vascular events, including stroke." | 8.86 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. ( Greer, DM, 2010) |
| "To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D." | 8.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention." | 8.84 | Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. ( Chaturvedi, S, 2008) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 8.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 8.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 8.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Combination therapy with dipyridamole and clopidogrel in stroke prevention and long-term outcomes in aspirin-intolerant patients with acute myocardial infarction (AMI) and previous stroke are unknown." | 7.91 | Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study. ( Chiang, CH; Huang, WC; Hung, CC; Kuo, FY; Liang, HL; Lin, KC; Liu, CP; Mar, GY; Tang, PL; Wang, MT; Yang, JS, 2019) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 7.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 7.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 7.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition." | 7.74 | Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. ( Hwang, SK; Kim, HH; Lee, HS; Liao, JK; Moskowitz, MA; Sawada, N; Soydan, G; Waeber, C; Zhou, Z, 2008) |
| "To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups." | 7.73 | Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. ( Diener, HC; Sacco, RL; Sivenius, J, 2005) |
| " This phenomenon may explain the clinical advantages of Aggrenox, known to reduce ischemic events in post stroke patients as proven in clinical trials, though an additional antithrombotic benefit beyond the platelet inhibition by aspirin alone." | 7.73 | Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. ( Atar, D; Hanley, D; Jilma, B; Malinin, A; Pokov, A; Serebruany, V; Ziai, W, 2006) |
| "To assess the cost effectiveness of aspirin 25 mg plus dipyridamole 200 mg twice daily in the secondary prevention of ischaemic stroke, according to the French social security perspective, using efficacy data from the second European Stroke Prevention Study (ESPS-2)." | 7.72 | Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France. ( Marissal, JP; Selke, B, 2004) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 7.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 6.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 6.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator." | 6.46 | Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010) |
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 5.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "Ischemic stroke is a leading cause of disability." | 5.34 | Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. ( Hallevi, H; Hazan-Halevy, I; Paran, E, 2007) |
| "Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke." | 5.20 | Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 5.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| "The recurrent stroke and cardiovascular event rates following discontinuation of aspirin plus extended-release dipyridamole (ASA + ERDP) or clopidogrel were compared to the event rates in the on-treatment populations (patients who had discontinued their antiplatelet medication due to an outcome event were kept in the on-treatment population in order not to underestimate the on-treatment stroke rate)." | 5.17 | Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. ( Bath, PM; Cotton, D; Diener, HC; Sacco, RL; Sha, N; Weber, R; Weimar, C, 2013) |
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 5.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| " We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients." | 5.15 | Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. ( Eisert, C; Fong, A; Hanley, D; Sani, Y; Schevchuck, A; Serebruany, V, 2011) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 5.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 5.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "Extended release dipyridamole (ERD) is widely used in patients after ischaemic stroke; however, the ability of this antithrombotic agent to be stored in different blood cells has never been explored in post-stroke patients." | 5.14 | Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. ( Atar, OD; Booze, C; Eisert, C; Hanley, D; Sabaeva, E; Serebruany, V, 2009) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 5.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "The combination of low-dose aspirin and dipyridamole is more effective than aspirin alone in reducing the risk of recurrent stroke and other major cardiovascular events in patients with a recent transient ischemic attack or minor stroke." | 5.14 | Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke. ( Algra, A; Dippel, DW; Halkes, P; Kappelle, LJ; Koudstaal, PJ; Maasland, L, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day." | 5.13 | Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Results of trials of aspirin and dipyridamole combined versus aspirin alone for the secondary prevention of vascular events after ischaemic stroke of presumed arterial origin are inconsistent." | 5.12 | Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2006) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 5.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "In the European Stroke Prevention Study (ESPS 2), oral administration of a fixed combination of 200 mg extended-release dipyridamole and 25 mg aspirin (twice daily) after ischemic stroke or transient ischemic attack, significantly reduced the risk of stroke compared to placebo as well as compared to aspirin or dipyridamole alone." | 5.12 | Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. ( Buell, U; Koch, KC; Noth, J; Nowak, B; Schaefer, WM; Weiss, PH, 2006) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| "PRoFESS is the largest secondary stroke prevention trial to date and will directly compare two antiplatelet regimens as well as the benefit of telmisartan versus placebo." | 5.12 | Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with ( Diener, HC; Sacco, R; Yusuf, S, 2007) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 5.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 5.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months." | 5.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| "In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial." | 5.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "30-day survivors of ischaemic stroke treated with low dose aspirin, modified-release dipyridamole; the coformulation of low dose aspirin plus modified-release dipyridamole, or no antiplatelet therapy." | 5.09 | Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. ( Chambers, M; Gladman, J; Hutton, J, 1999) |
| "The second European Stroke Prevention Study investigated the prevention of stroke and/or death in 6602 patients with transient ischaemic attack or stroke with aspirin (25 mg b." | 5.09 | Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). ( Bertrand-Hardy, JM; Darius, H; Diener, HC; Humphreys, M, 2001) |
| " Data from one randomised controlled trial showed no significant difference in benefit with aspirin versus placebo in asymptomatic carotid stenosis, but it is still reasonable to recommend aspirin (81-325 mg daily) for prevention of vascular events in these patients." | 5.01 | Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. ( de Borst, GJ; Halliday, A; Hamilton, G; Kakkos, S; McCabe, DJH; Murphy, SJX; Naylor, AR; Ricco, JB; Sillesen, H; Vega de Ceniga, M, 2019) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved." | 4.90 | Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 4.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| " The combination of acetylsalicylic acid (ASA) plus dipyridamole (DP) was more protective against recurrent stroke than ASA alone (RR = 0." | 4.89 | Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. ( Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA, 2013) |
| "Drugs that prevent platelets from sticking together-ie, aspirin, dipyridamole, and clopidogrel-are an important part of therapy to prevent recurrence of ischemic stroke of atherosclerotic origin." | 4.89 | Antiplatelet therapy to prevent recurrent stroke: Three good options. ( Mansoor, AH; Mujtaba, MT; Silver, B, 2013) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| "To identify confounding factors that may explain the incoherence between direct and indirect evidence in a published analysis comparing extended-release dipyridamole (ERDP) plus aspirin to clopidogrel for the reduction of stroke." | 4.88 | Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention. ( Dewilde, S; Hawkins, N, 2012) |
| "A 23-year-old woman developed ischemic stroke (IS) 8 to 12 hours after ingestion of sumatriptan (ST) and then developed mucosal bleeding secondary to acute thrombocytopenia likely due to dipyridamole (DP) on the 10th day poststroke." | 4.87 | Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy. ( Adams, C; Ames, PR; Dhirendra, A, 2011) |
| "The safety of fixed-dose combination aspirin-extended-release (ER) dipyridamole for stroke prevention in patients with ischemic heart disease is reviewed." | 4.86 | Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease. ( Crown, N; Mysak, T, 2010) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "Oral antiplatelet drugs, including aspirin, clopidogrel and extended-release dipyridamole, are widely prescribed for the secondary prevention of vascular events, including stroke." | 4.86 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. ( Greer, DM, 2010) |
| "In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women." | 4.85 | Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009) |
| " Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive." | 4.85 | Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009) |
| "To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D." | 4.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention." | 4.84 | Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. ( Chaturvedi, S, 2008) |
| "Low dose aspirin is effective in secondary stroke prevention." | 4.84 | Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. ( Kirshner, HS, 2007) |
| "In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke." | 4.84 | Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? ( Algra, A; Halkes, PH, 2007) |
| "Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation." | 4.84 | Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 4.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "Aspirin is not effective in the primary prevention of stroke." | 4.83 | Primary and secondary stroke prevention with antiplatelet drugs. ( Diener, HC, 2006) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 4.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "Aspirin is a relatively inexpensive and effective agent for secondary stroke prevention, and lower doses of aspirin appear as effective as higher doses." | 4.81 | Antiplatelet agents for secondary prevention of ischemic stroke. ( Delanty, N; Kantor, J; Majid, A, 2001) |
| " Dipyridamole co-formulated with aspirin has been shown to increase the relative reduction in risk of second stroke in patients with prior stroke/transient ischaemic attack beyond that obtaining with aspirin alone." | 4.81 | Dipyridamole may be used safely in patients with ischaemic heart disease. ( Bertrand-Hardy, JM; Humphreys, DM; Palluk, R; Schumacher, H; Street, J, 2002) |
| "At the acute phase of cerebral infarction, two recent large studies found that the use of aspirin reduces both mortality and the risk of the recurrence of stroke." | 4.80 | [Aspirin and cerebral ischemic accidents]. ( Bousser, MG; Crassard, I; Niclot, P, 2000) |
| "Aspirin is the treatment of first choice for long-term secondary prevention of vascular events in patients with confirmed non-cardioembolic ischaemic stroke or TIA." | 4.80 | Prevention of ischaemic stroke--antiplatelets. ( Brown, MM; McCabe, DJ, 2000) |
| " Classic antiplatelet therapy with aspirin to prevent occlusive stroke offers significant clinical benefit (20-25% risk reduction), yet is less effective than in prevention of coronary artery occlusion (up to 50% risk reduction of myocardial infarction in unstable angina)." | 4.80 | Antiplatelet agents in stroke prevention. combination therapy: present and future. ( Weksler, BB, 2000) |
| "To describe the pharmacology, pharmacokinetics, efficacy, and safety of a fixed-dose combination of aspirin and extended-release (ER) dipyridamole indicated for the secondary prevention of stroke." | 4.80 | Aggrenox: a fixed-dose combination of aspirin and dipyridamole. ( Hilleman, DE; Lenz, TL, 2000) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 4.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "Combination therapy with dipyridamole and clopidogrel in stroke prevention and long-term outcomes in aspirin-intolerant patients with acute myocardial infarction (AMI) and previous stroke are unknown." | 3.91 | Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study. ( Chiang, CH; Huang, WC; Hung, CC; Kuo, FY; Liang, HL; Lin, KC; Liu, CP; Mar, GY; Tang, PL; Wang, MT; Yang, JS, 2019) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 3.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 3.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "Despite changes in international guidelines, aspirin monotherapy should retain its position as the main antiplatelet agent for secondary prevention of non-cardioembolic ischaemic stroke." | 3.78 | Secondary stroke prevention: misguided by guidelines? ( Molenberghs, G; Vanstreels, L; Voigt, JU, 2012) |
| "We and others have previously demonstrated that nitric oxide (NO)-induced inhibition of platelet shape change is important in regulating platelet adhesion and aggregation, and therapeutic intervention of this pathway is clinically relevant for secondary prevention of stroke with dipyridamole." | 3.77 | Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change. ( Døskeland, SO; Holmsen, H; Jensen, BO; Kleppe, R; Kopperud, R; Nygaard, G; Selheim, F, 2011) |
| "Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization." | 3.76 | Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 3.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "In the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial, the combination of acetylsalicylic acid (50 mg) and extended-release dipyridamole (400 mg) (ASA+Dip) was compared with clopidogrel (75 mg) in patients with a recent transient ischaemic attack (TIA) or minor disabling stroke." | 3.74 | [Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial]. ( Kappelle, LJ, 2008) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "Clopidogrel and dipyridamole-aspirin are used frequently after stroke or transient ischemic attack." | 3.74 | Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack. ( Hills, NK; Johnston, SC, 2008) |
| "Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition." | 3.74 | Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. ( Hwang, SK; Kim, HH; Lee, HS; Liao, JK; Moskowitz, MA; Sawada, N; Soydan, G; Waeber, C; Zhou, Z, 2008) |
| "To assess the efficacy of aspirin plus extended-release dipyridamole compared with aspirin alone for the prevention of recurrent stroke among high-risk groups." | 3.73 | Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. ( Diener, HC; Sacco, RL; Sivenius, J, 2005) |
| "Our findings do not concur with the hypothesis that aspirin, dipyridamole, or the combination may be especially effective in preventing vascular events in patients with previous cerebral ischemia that was caused by LVD compared with SVD." | 3.73 | Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. ( Algra, A; Ariesen, MJ; Kappelle, LJ, 2006) |
| " This phenomenon may explain the clinical advantages of Aggrenox, known to reduce ischemic events in post stroke patients as proven in clinical trials, though an additional antithrombotic benefit beyond the platelet inhibition by aspirin alone." | 3.73 | Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. ( Atar, D; Hanley, D; Jilma, B; Malinin, A; Pokov, A; Serebruany, V; Ziai, W, 2006) |
| " The strict adherence to aspirin and dipyridamole has led to no stroke or progression of the vasculopathy for 8 years." | 3.73 | Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia. ( Hara, T; Kira, R; Ohga, S; Sanefuji, M; Torisu, H; Yoshiura, T, 2006) |
| "Aspirin is the drug of choice in most patients with acute stroke, if thrombolysis is contraindicated." | 3.72 | [Anticoagulation and antiaggregation in neurological patients]. ( Arnold, M; Mattle, HP; Nedeltchev, K, 2003) |
| "In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns." | 3.72 | Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. ( , 2003) |
| "To assess the cost effectiveness of aspirin 25 mg plus dipyridamole 200 mg twice daily in the secondary prevention of ischaemic stroke, according to the French social security perspective, using efficacy data from the second European Stroke Prevention Study (ESPS-2)." | 3.72 | Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France. ( Marissal, JP; Selke, B, 2004) |
| "Aspirin has been the mainstay of antiplatelet therapy in stroke prevention for 30 years." | 3.71 | Newer antiplatelet therapies in stroke prevention. ( Davis, SM; Donnan, GA, 2001) |
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 3.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "(1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart disease, combined treatment with aspirin + moderate-dose unfractionated heparin reduces the risk of relapse and death." | 3.70 | Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention. ( , 2000) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 2.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| "Many stroke survivors have severe dysphagia and are unable to take antithrombotic medications orally." | 2.75 | Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an open-label, case-control, two-centre study. ( Batista, LM; Crandell, D; Greer, DM; Lima, FO, 2010) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 2.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "The mechanism of stroke is believed to be thromboembolic in the majority of cases." | 2.73 | Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS). ( , 2007) |
| "Stroke is a leading cause of death worldwide and the first cause of disability in the Western world." | 2.48 | Antiplatelet treatment in primary and secondary stroke prevention in women. ( Acciarresi, M; Caso, V; Paciaroni, M; Pezzella, FR; Santalucia, P, 2012) |
| "Stroke is one of the leading causes of disability; most are due to atherothrombotic mechanisms." | 2.47 | Current status of antiplatelet agents to prevent stroke. ( Benavente, OR; Field, TS, 2011) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone." | 2.46 | Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. ( Fung, K; Simmons, BB; Yeo, A, 2010) |
| "Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator." | 2.46 | Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010) |
| "Absorption is a critical component of the pharmacokinetics for solid dosage forms administered orally." | 2.46 | Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. ( Conrado, DJ; Derendorf, H; Gonzalez, D, 2010) |
| "Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone." | 2.45 | Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? ( Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009) |
| "Stroke is a leading cause of death, disability, and dependence." | 2.44 | The approach to optimizing stroke care. ( Panagos, PD, 2008) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively." | 2.44 | Translational therapeutics of dipyridamole. ( Kim, HH; Liao, JK, 2008) |
| "Patients who have transient ischemic attack (TIA) or ischemic stroke are at a high risk of having a first or recurrent stroke." | 2.44 | Antiplatelet agents and randomized trials. ( Diener, HC, 2007) |
| "Aspirin has been shown to be as effective as warfarin in the prevention of noncardioembolic ischaemic stroke, with significantly fewer bleeding complications." | 2.43 | Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. ( Weinberger, J, 2005) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| "Dipyridamole was not more efficacious in the prevention of vascular death (relative risk [RR], 1." | 2.42 | Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. ( Algra, A; De Schryver, EL; van Gijn, J, 2003) |
| "Dipyridamole has been studied as an antiplatelet agent for several decades." | 2.42 | Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. ( Lenz, T; Wilson, A, 2003) |
| "Aspirin has been the first-line agent for stroke prevention for a long time." | 2.42 | Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke. ( Redman, AR; Ryan, GJ, 2004) |
| "Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia." | 2.41 | Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002) |
| "Stroke is a major cause of morbidity and mortality." | 2.41 | A benefit-risk assessment of agents used in the secondary prevention of stroke. ( MacWalter, RS; Shirley, CP, 2002) |
| "Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke." | 2.41 | Update on antiplatelet therapy for stroke prevention. ( Elkind, MS; Sacco, RL, 2000) |
| "Stroke is the third most common cause of adult mortality in the United States." | 2.41 | Antithrombotic drugs for secondary stroke prophylaxis. ( Pettigrew, LC, 2001) |
| "Stroke is the third leading cause of death in the United States." | 2.41 | Antiplatelet therapy in secondary stroke prevention. ( Crawford, KM; Talbert, RL, 2001) |
| "Stroke is the third most common cause of adult mortality in the United States." | 2.41 | Antithrombotic drugs for prevention of recurrent stroke. ( Pettigrew, LC; Williams, SC, 2002) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)." | 1.36 | Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010) |
| " In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)." | 1.35 | Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008) |
| "Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury." | 1.34 | TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007) |
| "Embolism is a dreaded complication of infective endocarditis (IE)." | 1.34 | Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. ( Anavekar, NS; Baddour, LM; Chandrasekaran, K; Haddad, C; Khandaker, MH; Mirzoyev, Z; Steckelberg, JM; Tleyjeh, IM; Wilson, WR, 2007) |
| "Ischemic stroke is a leading cause of disability." | 1.34 | Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. ( Hallevi, H; Hazan-Halevy, I; Paran, E, 2007) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking." | 1.32 | Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004) |
| "Stroke is highly prevalent in long-term care." | 1.31 | Clinical correlates and drug treatment of residents with stroke in long-term care. ( Lapane, KL; Quilliam, BJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.38) | 18.2507 |
| 2000's | 179 (68.06) | 29.6817 |
| 2010's | 75 (28.52) | 24.3611 |
| 2020's | 8 (3.04) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, MK | 1 |
| Cha, JK | 1 |
| Chang, DI | 1 |
| Kim, HY | 1 |
| Chung, JW | 1 |
| Jung, KH | 1 |
| Hong, KS | 2 |
| Chang, JY | 1 |
| Rha, JH | 1 |
| Park, JM | 1 |
| Kim, BK | 1 |
| Lee, SJ | 1 |
| Park, MS | 1 |
| Lee, KY | 1 |
| Shin, DI | 1 |
| Yoon, BW | 3 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Lim, ST | 1 |
| Murphy, SJX | 2 |
| Murphy, SM | 1 |
| Coughlan, T | 5 |
| O'Neill, D | 5 |
| Tierney, S | 4 |
| Egan, B | 4 |
| Collins, DR | 4 |
| McCarthy, AJ | 1 |
| Lim, SY | 1 |
| Smith, DR | 1 |
| Cox, D | 2 |
| McCabe, DJH | 2 |
| Scalia, L | 1 |
| Calderone, D | 1 |
| Capodanno, D | 1 |
| Woodhouse, LJ | 4 |
| Appleton, JP | 3 |
| Christensen, H | 3 |
| Dineen, RA | 3 |
| England, TJ | 3 |
| James, M | 3 |
| Krishnan, K | 3 |
| Montgomery, AA | 2 |
| Ranta, A | 3 |
| Robinson, TG | 3 |
| Sprigg, N | 5 |
| Bath, PM | 15 |
| Kimpton, J | 1 |
| Khong, T | 1 |
| Kasner, SE | 1 |
| Randall, B | 1 |
| Andersen, G | 2 |
| Iversen, HK | 1 |
| Roine, RO | 1 |
| Sjostrand, C | 1 |
| Rhodes, JF | 1 |
| Søndergaard, L | 1 |
| Hilkens, NA | 1 |
| Algra, A | 16 |
| Diener, HC | 26 |
| Csiba, L | 1 |
| Hacke, W | 1 |
| Kappelle, LJ | 7 |
| Koudstaal, PJ | 4 |
| Leys, D | 3 |
| Mas, JL | 1 |
| Sacco, RL | 9 |
| Greving, JP | 1 |
| Beridze, M | 2 |
| Duley, L | 2 |
| Flaherty, K | 2 |
| Havard, D | 1 |
| Heptinstall, S | 3 |
| Markus, HS | 5 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Scutt, P | 2 |
| Venables, GS | 2 |
| Barlas, RS | 1 |
| Loke, YK | 1 |
| Mamas, MA | 1 |
| Bettencourt-Silva, JH | 1 |
| Ford, I | 1 |
| Clark, AB | 1 |
| Bowles, KM | 1 |
| Metcalf, AK | 1 |
| Potter, JF | 1 |
| Myint, PK | 1 |
| Naylor, AR | 1 |
| Ricco, JB | 1 |
| Sillesen, H | 1 |
| Kakkos, S | 1 |
| Halliday, A | 1 |
| de Borst, GJ | 2 |
| Vega de Ceniga, M | 1 |
| Hamilton, G | 1 |
| Wang, MT | 1 |
| Liang, HL | 1 |
| Hung, CC | 1 |
| Tang, PL | 1 |
| Lin, KC | 1 |
| Chiang, CH | 1 |
| Kuo, FY | 1 |
| Yang, JS | 1 |
| Liu, CP | 1 |
| Mar, GY | 1 |
| Huang, WC | 1 |
| Levi, C | 1 |
| King, A | 2 |
| Madigan, J | 1 |
| Norris, J | 1 |
| Chung, Y | 1 |
| Rabe-Hesketh, S | 1 |
| Choi, IH | 1 |
| Zuurbier, SM | 1 |
| Vermeer, SE | 1 |
| Hilkens, PH | 1 |
| Roos, YB | 1 |
| Weimar, C | 3 |
| Cotton, D | 6 |
| Sha, N | 1 |
| Weber, R | 5 |
| Li, X | 1 |
| Zhou, G | 1 |
| Zhou, X | 1 |
| Zhou, S | 1 |
| Douiri, A | 1 |
| McKevitt, C | 1 |
| Emmett, ES | 1 |
| Rudd, AG | 1 |
| Wolfe, CD | 1 |
| Lee, M | 1 |
| Saver, JL | 2 |
| Rao, NM | 1 |
| Wu, YL | 1 |
| Ovbiagele, B | 3 |
| Malloy, RJ | 1 |
| Kanaan, AO | 1 |
| Silva, MA | 1 |
| Donovan, JL | 1 |
| Ding, D | 1 |
| Mansoor, AH | 1 |
| Mujtaba, MT | 1 |
| Silver, B | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Tuttolomondo, A | 1 |
| Pecoraro, R | 1 |
| Di Raimondo, D | 1 |
| Arnao, V | 1 |
| Clemente, G | 1 |
| Della Corte, V | 1 |
| Maida, C | 1 |
| Simonetta, I | 1 |
| Licata, G | 1 |
| Pinto, A | 1 |
| Sandercock, PA | 1 |
| Counsell, C | 1 |
| Tseng, MC | 1 |
| Cecconi, E | 1 |
| Tobin, WO | 4 |
| Kinsella, JA | 4 |
| Kavanagh, GF | 2 |
| O'Donnell, JS | 2 |
| McGrath, RT | 1 |
| Feeley, TM | 3 |
| Murphy, RP | 4 |
| McCabe, DJ | 6 |
| de Vos-Koppelaar, NC | 1 |
| Kerkhoff, H | 1 |
| de Vogel, EM | 1 |
| Zock, E | 1 |
| Dieleman, HG | 1 |
| Davidai, G | 1 |
| Gorelick, P | 4 |
| Lipton, RB | 1 |
| Sacco, R | 3 |
| Robson, K | 1 |
| Dineen, R | 1 |
| Pocock, S | 3 |
| Gross, BA | 1 |
| Albuquerque, FC | 1 |
| Rothlisberger, JM | 1 |
| Fabiaña, N | 1 |
| Ramaswami, AP | 1 |
| Ang, ES | 1 |
| De Silva, DA | 1 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Olesen, JB | 1 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Kristensen, SL | 1 |
| Gislason, G | 1 |
| Torp-Pedersen, C | 1 |
| Murphy, SJ | 1 |
| Coughlan, CA | 1 |
| Tobin, O | 1 |
| Kinsella, J | 1 |
| Lonergan, R | 1 |
| Gutkin, M | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Halkes, PH | 4 |
| Gray, LJ | 2 |
| Guiraud-Chaumeil, B | 2 |
| Yatsu, FM | 1 |
| Sztriha, LK | 1 |
| Vécsei, L | 1 |
| Albers, GW | 4 |
| Amarenco, P | 1 |
| Easton, JD | 2 |
| Teal, P | 3 |
| Diener, C | 1 |
| Hoover, PL | 1 |
| Mold, JW | 1 |
| England, T | 1 |
| Willmot, MR | 1 |
| Zhao, L | 3 |
| Sare, GM | 1 |
| Chaturvedi, S | 2 |
| Anderson, CS | 1 |
| Alexandrov, AV | 1 |
| Alagona, P | 1 |
| Kent, DM | 1 |
| Thaler, DE | 1 |
| Yusuf, S | 5 |
| Ounpuu, S | 2 |
| Lawton, WA | 2 |
| Palesch, Y | 3 |
| Martin, RH | 4 |
| Bath, P | 4 |
| Bornstein, N | 2 |
| Chan, BP | 2 |
| Chen, ST | 2 |
| Cunha, L | 2 |
| Dahlöf, B | 2 |
| De Keyser, J | 2 |
| Donnan, GA | 5 |
| Estol, C | 3 |
| Gu, V | 2 |
| Hermansson, K | 3 |
| Hilbrich, L | 2 |
| Kaste, M | 3 |
| Lu, C | 2 |
| Machnig, T | 2 |
| Pais, P | 2 |
| Roberts, R | 3 |
| Skvortsova, V | 2 |
| Toni, D | 2 |
| Vandermaelen, C | 2 |
| Voigt, T | 2 |
| Weber, M | 2 |
| Panagos, PD | 1 |
| Lam, SK | 1 |
| Owen, A | 1 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Rouhl, RP | 1 |
| Lodder, J | 1 |
| Lees, KR | 3 |
| Selim, M | 1 |
| Minnerup, J | 1 |
| Schäbitz, WR | 1 |
| Hart, RG | 1 |
| Hegge, KA | 1 |
| van Gijn, J | 8 |
| Furlan, AJ | 1 |
| Balucani, C | 1 |
| Cordonnier, C | 2 |
| Usman, MH | 1 |
| Notaro, LA | 1 |
| Nagarakanti, R | 1 |
| Brahin, E | 1 |
| Dessain, S | 1 |
| Gracely, E | 1 |
| Ezekowitz, MD | 2 |
| Khalil, S | 1 |
| Mohanaruban, K | 1 |
| Haq, S | 1 |
| De Schryver, EL | 6 |
| Lökk, J | 1 |
| Beckman, JA | 1 |
| Adams, C | 1 |
| Dhirendra, A | 1 |
| Ames, PR | 1 |
| Serebruany, V | 4 |
| Sabaeva, E | 1 |
| Booze, C | 1 |
| Atar, OD | 1 |
| Eisert, C | 2 |
| Hanley, D | 4 |
| Sharma, JC | 2 |
| Vassallo, M | 1 |
| Ross, IN | 1 |
| Meyer, D | 1 |
| Diedler, J | 1 |
| Ahmed, N | 1 |
| Sykora, M | 1 |
| Uyttenboogaart, M | 1 |
| Overgaard, K | 2 |
| Luijckx, GJ | 1 |
| Soinne, L | 1 |
| Ford, GA | 1 |
| Wahlgren, N | 1 |
| Ringleb, P | 1 |
| Burke, JP | 1 |
| Sander, S | 1 |
| Shah, H | 2 |
| Zarotsky, V | 1 |
| Henk, H | 1 |
| Simmons, BB | 1 |
| Yeo, A | 1 |
| Fung, K | 1 |
| Crown, N | 1 |
| Mysak, T | 1 |
| Batista, LM | 1 |
| Crandell, D | 1 |
| Lima, FO | 1 |
| Greer, DM | 2 |
| Arauz, A | 1 |
| Calleja, J | 1 |
| Vallejo, E | 1 |
| Quintero, L | 1 |
| Dippel, DW | 2 |
| Maasland, L | 1 |
| Halkes, P | 1 |
| d'Esterre, CD | 1 |
| Lee, TY | 1 |
| Melani, A | 1 |
| Cipriani, S | 1 |
| Corti, F | 1 |
| Pedata, F | 1 |
| Conrado, DJ | 1 |
| Gonzalez, D | 1 |
| Derendorf, H | 2 |
| Jensen, BO | 1 |
| Kleppe, R | 1 |
| Kopperud, R | 1 |
| Nygaard, G | 1 |
| Døskeland, SO | 1 |
| Holmsen, H | 1 |
| Selheim, F | 1 |
| Sani, Y | 2 |
| Schevchuck, A | 2 |
| Fong, A | 2 |
| Kral, M | 1 |
| Herzig, R | 1 |
| Sanak, D | 1 |
| Skoloudik, D | 1 |
| Vlachova, I | 1 |
| Bartkova, A | 1 |
| Hlustik, P | 1 |
| Kovacik, M | 1 |
| Kanovsky, P | 1 |
| Maron, BA | 1 |
| Shekar, PS | 1 |
| Goldhaber, SZ | 1 |
| Field, TS | 1 |
| Benavente, OR | 1 |
| Lièvre, MM | 1 |
| Moulin, P | 1 |
| Thivolet, C | 1 |
| Rodier, M | 1 |
| Rigalleau, V | 1 |
| Penfornis, A | 1 |
| Pradignac, A | 1 |
| Ovize, M | 1 |
| Pokov, I | 1 |
| Thevathasan, L | 1 |
| Khan, M | 2 |
| Kamal, AK | 3 |
| Röther, J | 1 |
| Uchiyama, S | 1 |
| Ikeda, Y | 1 |
| Urano, Y | 1 |
| Horie, Y | 1 |
| Yamaguchi, T | 1 |
| Guthrie, R | 1 |
| Hogg, C | 1 |
| Tracy, M | 1 |
| Bhattacharya, P | 1 |
| Vinisko, R | 1 |
| Aw, D | 1 |
| Wanke, I | 1 |
| Möller-Hartmann, C | 1 |
| Gizewski, ER | 1 |
| Blatchford, J | 1 |
| Demchuk, AM | 1 |
| Forsting, M | 1 |
| Warach, S | 1 |
| Diehl, A | 1 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Geeganage, CM | 1 |
| Chen, C | 1 |
| Topol, EJ | 1 |
| Dengler, R | 2 |
| Bath, MW | 1 |
| Dewilde, S | 1 |
| Hawkins, N | 1 |
| Arnarsdottir, L | 1 |
| Hjalmarsson, C | 1 |
| Bokemark, L | 1 |
| Andersson, B | 1 |
| Brenck, J | 1 |
| Caso, V | 1 |
| Santalucia, P | 1 |
| Acciarresi, M | 1 |
| Pezzella, FR | 1 |
| Paciaroni, M | 2 |
| Worthmann, H | 1 |
| Schumacher, H | 2 |
| Schwartz, A | 1 |
| Eisert, WG | 2 |
| Lichtinghagen, R | 1 |
| Weissenborn, K | 1 |
| Collins, R | 1 |
| Vanstreels, L | 1 |
| Molenberghs, G | 1 |
| Voigt, JU | 1 |
| Molnar, T | 1 |
| Szabo, Z | 1 |
| Bartha, E | 1 |
| Illes, Z | 1 |
| McGrath, RA | 1 |
| Wadiwala, MF | 1 |
| Milionis, H | 1 |
| Michel, P | 1 |
| Warlow, C | 1 |
| Davis, SM | 2 |
| Mehta, P | 1 |
| MacWalter, RS | 1 |
| Shirley, CP | 1 |
| Arnold, M | 1 |
| Nedeltchev, K | 1 |
| Mattle, HP | 1 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Connolly, SJ | 1 |
| Serebruany, VL | 4 |
| Malinin, AI | 2 |
| Sane, DC | 2 |
| Sivenius, J | 3 |
| Lenz, T | 1 |
| Wilson, A | 1 |
| Aslanyan, S | 1 |
| Fazekas, F | 1 |
| Weir, CJ | 1 |
| Horner, S | 1 |
| Jonas, S | 2 |
| Grieco, G | 2 |
| Christian, JB | 1 |
| Lapane, KL | 2 |
| Toppa, RS | 1 |
| Haberl, R | 1 |
| Redman, AR | 1 |
| Ryan, GJ | 1 |
| Moonis, M | 1 |
| Fisher, M | 1 |
| Hanley, DF | 1 |
| Atar, D | 3 |
| Ferguson, JJ | 1 |
| Yamagata, K | 1 |
| Ichinose, S | 1 |
| Tagami, M | 1 |
| Ruel, M | 1 |
| Masters, RG | 1 |
| Rubens, FD | 1 |
| Bédard, PJ | 1 |
| Pipe, AL | 1 |
| Goldstein, WG | 1 |
| Hendry, PJ | 1 |
| Mesana, TG | 1 |
| Marissal, JP | 1 |
| Selke, B | 1 |
| Lindberg, M | 1 |
| Jilma, B | 2 |
| Takserman, A | 1 |
| Hennekens, CH | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Nicholls, C | 1 |
| Sani, M | 1 |
| Leonardi-Bee, J | 3 |
| Bousser, MG | 2 |
| Davalos, A | 1 |
| Yatsu, F | 1 |
| Dewey, ME | 1 |
| Weinberger, J | 2 |
| Fletcher, S | 1 |
| Weaver, C | 1 |
| May, J | 1 |
| Fox, S | 1 |
| Willmot, M | 1 |
| Heptinstal, S | 1 |
| Ringleb, PA | 1 |
| Schwark, C | 1 |
| Schwaninger, M | 1 |
| Schellinger, PD | 1 |
| Morton, JA | 1 |
| Newton, J | 1 |
| Gray, CS | 1 |
| Bernstein, RA | 1 |
| Gebel, JM | 1 |
| Gorelick, PB | 2 |
| Jamieson, DG | 2 |
| Parekh, A | 1 |
| Sudlow, C | 2 |
| Szapáry, L | 1 |
| Ariesen, MJ | 1 |
| Malinin, A | 1 |
| Ziai, W | 1 |
| Pokov, A | 1 |
| Schaper, W | 1 |
| Petersen, P | 1 |
| Husted, SE | 2 |
| Boysen, G | 1 |
| Johnsen, SP | 1 |
| Gray, L | 1 |
| Weaver, CS | 1 |
| Caplan, LR | 1 |
| Sanefuji, M | 1 |
| Ohga, S | 2 |
| Kira, R | 1 |
| Yoshiura, T | 1 |
| Torisu, H | 1 |
| Hara, T | 2 |
| Norrving, B | 1 |
| Horton, HL | 1 |
| Chang, YJ | 1 |
| Ryu, SJ | 1 |
| Lee, TH | 1 |
| Habib, GB | 1 |
| Chairangsarit, P | 1 |
| Sithinamsuwan, P | 1 |
| Niyasom, S | 1 |
| Udommongkol, C | 1 |
| Nidhinandana, S | 1 |
| Suwantamee, J | 1 |
| Schaefer, WM | 1 |
| Koch, KC | 1 |
| Nowak, B | 1 |
| Noth, J | 1 |
| Buell, U | 1 |
| Weiss, PH | 1 |
| Busse, O | 1 |
| Grond, M | 1 |
| Kramer, J | 1 |
| Abraham, J | 1 |
| Teven, CM | 1 |
| Jones, PA | 1 |
| Schindler, B | 1 |
| Hill, MD | 1 |
| Einhäupl, K | 1 |
| Moussouttas, M | 1 |
| Al-Bahrani, A | 1 |
| Taha, S | 1 |
| Shaath, H | 1 |
| Bakhiet, M | 1 |
| Liao, JK | 3 |
| Anavekar, NS | 2 |
| Tleyjeh, IM | 1 |
| Mirzoyev, Z | 1 |
| Steckelberg, JM | 1 |
| Haddad, C | 1 |
| Khandaker, MH | 1 |
| Wilson, WR | 1 |
| Chandrasekaran, K | 1 |
| Baddour, LM | 1 |
| Aldandashi, S | 1 |
| Noor, R | 1 |
| Wang, CX | 1 |
| Uddin, G | 1 |
| Shuaib, A | 1 |
| Gogol, M | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| Moll, FL | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Macdonald, S | 1 |
| Hallevi, H | 2 |
| Hazan-Halevy, I | 1 |
| Paran, E | 2 |
| Fintel, DJ | 1 |
| Kirshner, HS | 1 |
| Sedrakyan, A | 1 |
| Shih, C | 1 |
| Poulsen, TS | 1 |
| Hankey, GJ | 1 |
| Kim, HH | 2 |
| Rojas, A | 1 |
| González, I | 1 |
| Figueroa, H | 1 |
| Hazan-Hallevi, I | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Adams, RJ | 1 |
| Albers, G | 1 |
| Alberts, MJ | 1 |
| Benavente, O | 1 |
| Furie, K | 1 |
| Goldstein, LB | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Johnston, SC | 2 |
| Katzan, I | 1 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Schwamm, LH | 1 |
| Hills, NK | 1 |
| Verro, P | 1 |
| Nguyen, D | 1 |
| Thijs, V | 1 |
| Lemmens, R | 1 |
| Fieuws, S | 1 |
| Schwartz, NE | 1 |
| Sawada, N | 1 |
| Soydan, G | 1 |
| Lee, HS | 1 |
| Zhou, Z | 1 |
| Hwang, SK | 1 |
| Waeber, C | 1 |
| Moskowitz, MA | 1 |
| Henney, JE | 1 |
| SoRelle, R | 1 |
| Chambers, M | 1 |
| Hutton, J | 1 |
| Gladman, J | 1 |
| Ranhosky, A | 1 |
| Crassard, I | 1 |
| Niclot, P | 1 |
| Joubert, J | 1 |
| McLean, CA | 1 |
| Reid, CM | 1 |
| Davel, D | 1 |
| Pilloy, W | 1 |
| Delport, R | 1 |
| Steyn, L | 1 |
| Walker, AR | 1 |
| Elkind, MS | 1 |
| Klijn, CJ | 1 |
| van Buren, PA | 1 |
| Tulleken, CA | 1 |
| Eikelboom, BC | 1 |
| Cohen, SN | 1 |
| Gondek, K | 1 |
| Sarasin, FP | 1 |
| Gaspoz, JM | 1 |
| Bounameaux, H | 1 |
| Niessen, LW | 1 |
| Limburg, M | 1 |
| Gallai, V | 1 |
| Brown, MM | 1 |
| Devuyst, G | 1 |
| Bogousslavsky, J | 1 |
| Weksler, BB | 1 |
| Lenz, TL | 1 |
| Hilleman, DE | 1 |
| Siegel, AM | 1 |
| Sandor, P | 1 |
| Kollias, SS | 1 |
| Baumgartner, RW | 1 |
| Bergmann, SR | 1 |
| Scheen, AJ | 1 |
| Pettigrew, LC | 2 |
| Kipp, A | 1 |
| Darius, H | 1 |
| Bertrand-Hardy, JM | 2 |
| Humphreys, M | 1 |
| Quilliam, BJ | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Lowry, DR | 1 |
| Tokunaga, Y | 1 |
| Suita, S | 1 |
| Matsushima, T | 1 |
| Müller, TH | 1 |
| Majid, A | 1 |
| Delanty, N | 1 |
| Kantor, J | 1 |
| Hansen, DB | 1 |
| Brass, LM | 2 |
| Lalouschek, W | 1 |
| Lang, W | 1 |
| Müllner, M | 1 |
| Dalton, B | 1 |
| Papoushek, C | 1 |
| Evans, MF | 1 |
| Crawford, KM | 1 |
| Talbert, RL | 1 |
| Humphreys, DM | 1 |
| Street, J | 1 |
| Palluk, R | 1 |
| Williams, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Randomized Strategy Trial Comparing Detection of Silent Ischemia With no Detection of Silent Ischemia in Asymptomatic Patients With Type 2 Diabetes Mellitus. Effects on Cardiovascular Events.[NCT00627783] | 642 participants (Actual) | Interventional | 2000-12-31 | Terminated (stopped due to Poor recruiting status) | |||
| Functional and Anatomic Imaging Versus No Testing in Asymptomatic High-risk Diabetic Patients[NCT04388280] | 400 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | |||
| JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid[NCT00311402] | Phase 3 | 1,295 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744] | 3,400 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | |||
| ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial[NCT00161070] | Phase 4 | 4,500 participants | Interventional | 1997-07-31 | Completed | ||
| Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI[NCT00767663] | Phase 4 | 30 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 9 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 16 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 12 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 7 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 71 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 55 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 45 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 32 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 13 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 13 |
This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 51 |
This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 11 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 6 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 39 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 0 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 1 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 3 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 3 |
97 reviews available for dipyridamole and Stroke
| Article | Year |
|---|---|
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolyt | 2022 |
Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature.
Topics: Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2019 |
[Secondary prevention with clopidogrel after TIA or stroke].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; N | 2013 |
The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Topics: Aged; Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal | 2013 |
Antiplatelet therapy to prevent recurrent stroke: Three good options.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Secon | 2013 |
Stroke subtypes and their possible implication in stroke prevention drug strategies.
Topics: Animals; Antihypertensive Agents; Aspirin; Atherosclerosis; Blood Pressure; Dipyridamole; Humans; Pl | 2013 |
Oral antiplatelet therapy for acute ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle | 2014 |
Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2015 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; I | 2008 |
Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2008 |
Stroke and atherothrombosis: an update on the role of antiplatelet therapy.
Topics: Atherosclerosis; Delayed-Action Preparations; Dipyridamole; Embolism, Cholesterol; Humans; Platelet | 2008 |
The approach to optimizing stroke care.
Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Emergenc | 2008 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
ESPRIT: is aspirin plus dipyridamole superior to aspirin alone in TIA or minor stroke patients?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; H | 2008 |
Multifunctional actions of approved and candidate stroke drugs.
Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha | 2009 |
What's new in stroke? The top 10 studies of 2006-2008. Part I.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
Antiplatelet agents for prevention of recurrent ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic | 2009 |
Antiplatelet drugs for ischemic stroke prevention.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; | 2009 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Com | 2009 |
Secondary stroke prevention with antithrombotic drugs.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Cyclooxygenase Inhibitors; Dipyridamole; Drug | 2010 |
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, | 2009 |
Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy.
Topics: Acute Disease; Adult; Brain Ischemia; Dipyridamole; Female; Hemorrhage; Humans; Iatrogenic Disease; | 2011 |
Antiplatelets and stroke outcomes: state of the science.
Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy | 2009 |
Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Topics: American Heart Association; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; I | 2010 |
Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Drug-Related Side | 2010 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Second | 2010 |
Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits.
Topics: Animals; Cerebrovascular Circulation; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Hum | 2010 |
Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia.
Topics: Animals; Brain Ischemia; Carotid Artery, Common; Dipyridamole; Disease Models, Animal; Humans; Infus | 2010 |
Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke.
Topics: Administration, Oral; Anticoagulants; Clopidogrel; Dipyridamole; Humans; Intestinal Absorption; Plat | 2010 |
Oral antiplatelet therapy in stroke prevention. Minireview.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Ischemic Attack | 2010 |
Current status of antiplatelet agents to prevent stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
New insights in antiplatelet therapy for patients with ischemic stroke.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I | 2011 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Investigating incoherence gives insight: clopidogrel is equivalent to extended-release dipyridamole plus aspirin in secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Dipyridamole; Drug Therapy, Combination; H | 2012 |
Antiplatelet therapy in cerebrovascular disorders.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Platelet Aggr | 2012 |
Antiplatelet treatment in primary and secondary stroke prevention in women.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; Naphthalenes; Platele | 2012 |
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S | 2013 |
Aspirin in the prophylaxis of coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi | 2002 |
A benefit-risk assessment of agents used in the secondary prevention of stroke.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Clinical | 2002 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Dipyridamole; | 2003 |
Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease.
Topics: Death, Sudden, Cardiac; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction; Plat | 2003 |
Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Clopidogrel; Dipyridamole | 2003 |
Potential value of triple antiplatelet therapy for secondary stroke prevention.
Topics: Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; | 2003 |
Aspirin and stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Platelet Aggregation I | 2003 |
Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Delayed-Action | 2004 |
Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Human | 2003 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Hu | 2005 |
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans | 2005 |
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates | 2005 |
What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack?
Topics: Aspirin; Dipyridamole; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Platelet Aggrega | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
Dipyridamole, an underestimated vascular protective drug.
Topics: Adenosine; Angina Pectoris; Animals; Atherosclerosis; Coronary Circulation; Coronary Vessels; Dipyri | 2005 |
Primary and secondary stroke prevention with antiplatelet drugs.
Topics: Aspirin; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke; Treatment Failure | 2006 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Pl | 2006 |
How much esprit is in ESPRIT?
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Str | 2006 |
[Platelet-function inhibitors in the secondary prevention of ischemic stroke].
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Middle Aged; Platelet A | 2006 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2007 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' resu
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, C | 2007 |
The PRoFESS trial: future impact on secondary stroke prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2007 |
Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Family P | 2007 |
Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stro | 2007 |
Antiplatelet therapy for stroke prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel | 2007 |
Translational therapeutics of dipyridamole.
Topics: Acute Coronary Syndrome; Animals; Cyclic AMP; Cyclic GMP; Dipyridamole; Disease Models, Animal; Endo | 2008 |
Antiplatelet agents and randomized trials.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; P | 2007 |
Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combi | 2008 |
[Aspirin and cerebral ischemic accidents].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Infarction; Clinica | 2000 |
Update on antiplatelet therapy for stroke prevention.
Topics: Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Dose-Response Relation | 2000 |
Antiplatelet agents for stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2000 |
Prevention of ischaemic stroke--antiplatelets.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Pl | 2000 |
Antiplatelet agents in stroke prevention. combination therapy: present and future.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Dipyridamole; Humans; Immunoglobulin Fab Fr | 2000 |
Aggrenox: a fixed-dose combination of aspirin and dipyridamole.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical T | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
[Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemic A | 2000 |
Antithrombotic drugs for secondary stroke prophylaxis.
Topics: Adult; Aspirin; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggre | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction.
Topics: Aspirin; Blood Platelets; Cell Communication; Cerebral Arteries; Clinical Trials, Phase I as Topic; | 2001 |
Antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Humans; Myocard | 2001 |
Antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Com | 2001 |
Dipyridamole may be used safely in patients with ischaemic heart disease.
Topics: Dipyridamole; Humans; Ischemic Attack, Transient; Myocardial Ischemia; Randomized Controlled Trials | 2002 |
Antithrombotic drugs for prevention of recurrent stroke.
Topics: Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Fibrinolytic Agents; F | 2002 |
43 trials available for dipyridamole and Stroke
| Article | Year |
|---|---|
Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial.
Topics: Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Headache; Humans; Ischemic At | 2022 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke.
Topics: Adolescent; Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Foramen Ov | 2020 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal, Disse | 2019 |
Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
Topics: Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; | 2013 |
The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE).
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Headache; Humans; Ischemic Attack, Transie | 2014 |
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation | 2015 |
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2017 |
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Drug Tolerance; | 2008 |
Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS).
Topics: Anticoagulants; Aortic Dissection; Aspirin; Clinical Protocols; Clopidogrel; Diagnostic Imaging; Dip | 2007 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Cogn | 2008 |
Dipyridamole-associated headache in stroke patients--interindividual differences?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Drug Therapy, Combination; Femal | 2009 |
Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Delayed-Action Preparations; | 2009 |
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla | 2010 |
Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an open-label, case-control, two-centre study.
Topics: Aged; Aggrecans; Case-Control Studies; Cerebral Infarction; Deglutition Disorders; Delayed-Action Pr | 2010 |
Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke.
Topics: Aspirin; Dipyridamole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combinat | 2010 |
Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Atherosclerosis; Biomarkers; Case-Control Studies; | 2011 |
Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
Topics: Adult; Aged; Aspirin; Blood Platelets; Blood Specimen Collection; Dipyridamole; Drug Therapy, Combin | 2011 |
Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Aspirin; Clopidogrel; Dipyridamole; Double-Blind Method; D | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening.
Topics: Aged; Ambulatory Care; Asymptomatic Diseases; Cause of Death; Chi-Square Distribution; Diabetes Comp | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Comorbidity; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2012 |
Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Chemokine CCL2; Dipyridamole; D | 2012 |
What is better antiplatelet agent to prevent recurrent stroke?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2012 |
Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage?
Topics: Adenosine Diphosphate; Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Caps | 2003 |
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up | 2003 |
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
Topics: Aged; Antigens, CD; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; CD40 Ligand; Di | 2004 |
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog | 2005 |
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Dose titration to reduce dipyridamole-related headache.
Topics: Aged; Aspirin; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination; Female; Headac | 2006 |
Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study.
Topics: Aged; Aspirin; Brain Ischemia; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination | 2005 |
Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Circulation; Coronary Vessels; Dipyridamole; Drug Therapy | 2006 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Be | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Topics: Aged; Aged, 80 and over; Aspirin; Cost-Benefit Analysis; Decision Support Techniques; Dipyridamole; | 1999 |
Cardiac safety in the European Stroke Prevention Study 2 (ESPS2).
Topics: Angina Pectoris; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Longitudinal Studies; My | 2001 |
Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction.
Topics: Aspirin; Blood Platelets; Cell Communication; Cerebral Arteries; Clinical Trials, Phase I as Topic; | 2001 |
125 other studies available for dipyridamole and Stroke
| Article | Year |
|---|---|
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta | 2022 |
Intensive antiplatelet therapy with three agents does not reduce risk of another stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke | 2020 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2018 |
Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study.
Topics: Aged; Case-Control Studies; Cerebral Hemorrhage; Clopidogrel; Dipyridamole; Disease-Free Survival; D | 2019 |
Avoiding zero between-study variance estimates in random-effects meta-analysis.
Topics: Bayes Theorem; Computer Simulation; Depression; Dipyridamole; Exercise; Humans; Likelihood Functions | 2013 |
Long-term effects of secondary prevention on cognitive function in stroke patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cognition Disorders; Dipyridamole; Female | 2013 |
Implications of aspirin biochemistry in the pathobiology of ischemic cerebrovascular disease.
Topics: Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Random | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Enzyme-Linked Immunosorbent Assay; Female; Humans; | 2014 |
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; | 2014 |
Antiplatelets Versus Anticoagulation for Cervical Arterial Dissection.
Topics: Anticoagulants; Aortic Dissection; Aspirin; Carotid Artery, Internal, Dissection; Cervical Vertebrae | 2015 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; | 2015 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr | 2016 |
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions; | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Germany; Humans; Multicenter Studies | 2008 |
Does Aggrenox (aspirin/dipyridamole) reduce the risk of recurrent stroke to a greater degree than aspirin alone?
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet A | 2008 |
The PRoFESS trial results: what went wrong?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlled T | 2008 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridam | 2008 |
Is the finding of the PROFESS study consistent with predictions of network meta-analysis?
Topics: Aspirin; Bayes Theorem; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2008 |
[Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Aspirin; Benzimida | 2008 |
PRoFESS.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Clopido | 2009 |
Antiplatelets for stroke prevention: implications of the PRoFESS trial.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, | 2009 |
Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Arteries; Dipyridamole; Drug Therapy, Combination; Female; H | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combi | 2009 |
The use of aspirin and dipyridamole in the treatment of acute ischaemic stroke/transient ischaemic attack: an audit-based discussion.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Medical Audit; | 2009 |
ProFESS trial: any lessons to learn for future anti-platelet trials?
Topics: Aged; Aspirin; Brain; Cerebral Arteries; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Femal | 2009 |
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh | 2010 |
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema | 2010 |
Prevalence of silent myocardial ischemia in single and multiple lacunar infarcts and large vessel disease stroke.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Blood Vessels; Brain Infarction; Dipyridamole; Exer | 2010 |
Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Topics: Blood Platelets; Cell Adhesion Molecules; Cell Shape; Cyclic AMP; Cyclic AMP-Dependent Protein Kinas | 2011 |
Paradoxical embolism.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dyspnea; Echocardiography, Transesophageal; Embolism, Para | 2010 |
Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Dose-Response Relationship | 2012 |
What is the best antiplatelet agent for prevention of recurrent stroke in Pakistani patients? Do combinations offer significant advantages in the South Asian context?
Topics: Asian People; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medicine | 2010 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B | 2010 |
Calculation of numbers-needed-to-treat in parallel group trials assessing ordinal outcomes: case examples from acute stroke and stroke prevention.
Topics: Aged; Algorithms; Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Confide | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
Secondary stroke prevention: misguided by guidelines?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Pla | 2012 |
“ Cerebrovascular stressing”: dipyridamole-induced S100B elevation predicts ischemic cerebrovascular events.
Topics: Biomarkers; Coronary Artery Disease; Dipyridamole; Female; Follow-Up Studies; Humans; Ischemic Attac | 2013 |
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Longitu | 2013 |
Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Platelet Aggregation I | 2002 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
Aspirin therapy should be first line: probably, but watch this space.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Synergism; Humans; Myocardial Isc | 2002 |
[Anticoagulation and antiaggregation in neurological patients].
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopid | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
Topics: Anticoagulants; Arterial Occlusive Diseases; Asia, Southeastern; Aspirin; Brain Ischemia; Dipyridamo | 2003 |
Antiplatelet agents. European perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Europe; Hum | 2003 |
[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidaz | 2003 |
Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Brain Isc | 2003 |
Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents.
Topics: Aged; Anticoagulants; Aspirin; Databases, Factual; Dipyridamole; Drug Therapy, Combination; Drug Uti | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
[ASS and dipyridamole combination. A decisive contribution to secondary prevention after stroke].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
[Secondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?].
Topics: Aspirin; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ische | 2003 |
[Secondary prevention after stroke. Doubled performs better].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; | 2003 |
[After stroke or TIA. Double protection by second platelet inhibitor].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
Noncompliance in antiplatelet trials: the AGATE trial perspective.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; | 2004 |
Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antioxidants; Carbazoles; Carvedilol; Cell Death; Cell Hypoxia; Cells, Cultured | 2004 |
Late incidence and determinants of stroke after aortic and mitral valve replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral | 2004 |
Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France.
Topics: Adolescent; Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Confidence Intervals; Cost | 2004 |
[Asasantin Retard or Persantin Retard+ASA?].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Delayed-Action Preparations; Dipyridamole; Drug Com | 2004 |
Antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Humans; Myocardial Infarction; Patient | 2004 |
Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations.
Topics: Adult; Aged; Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, | 2005 |
Counting the true cost of antiplatelet therapy for stroke prevention.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Dipyridam | 2005 |
Use of dipyridamole in patients with recent stroke or TIA.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2005 |
Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Ther | 2005 |
Prevention of stroke recurrence.
Topics: Aged; Clopidogrel; Dipyridamole; Endarterectomy, Carotid; Humans; Platelet Aggregation Inhibitors; S | 2003 |
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Male; Middle | 2006 |
Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
Topics: Aged; Aspirin; Cell Culture Techniques; Dipyridamole; Dose-Response Relationship, Drug; Drug Resista | 2006 |
[Peroral antithrombotic treatment].
Topics: Administration, Oral; Antifibrinolytic Agents; Aspirin; Dipyridamole; Drug Therapy, Combination; Hum | 2006 |
Antiplatelet therapy in stroke prevention: present and future.
Topics: Aspirin; Blood Platelets; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Random | 2006 |
Moyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta-Thalassemia; Carotid Arteries; Di | 2006 |
Dipyridamole plus aspirin: the best regimen for stroke prevention after noncardioembolic focal cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Human | 2006 |
Dipyridamole with aspirin for secondary stroke prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; R | 2006 |
Secondary stroke prevention and antiplatelet therapy.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet A | 2006 |
Dipyridamole plus aspirin for stroke prevention.
Topics: Aspirin; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
Clinical trials and dipyridamole formulation selection.
Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug | 2007 |
Role of antiplatelets in carotid artery stenting.
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Dipyridamole | 2007 |
[Combination of acetylsalicylic acid with dipyridamole is better than acetylsalicylic acid monotherapy].
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Platelet Agg | 2006 |
Stroke: the dashed hopes of neuroprotection.
Topics: Acute Disease; Aspirin; Benzenesulfonates; Carotid Arteries; Clopidogrel; Dipyridamole; Europe; Huma | 2007 |
Emerging therapies: ESPRIT.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 2007 |
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem | 2007 |
Update on the use of antiplatelet agents in secondary stroke prevention.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, Cholester | 2007 |
Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Administration Sche | 2007 |
Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats.
Topics: Animals; Aspirin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Dipyridamole; Drug Therap | 2007 |
Combination shows no advantage over aspirin alone.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cell Adhes | 2007 |
Improving depiction of benefits and harms: analyses of studies of well-known therapeutics and review of high-impact medical journals.
Topics: Antipsychotic Agents; Appetite Depressants; Aspirin; Aspirin, Dipyridamole Drug Combination; Contrac | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Antiplatelet agents for stroke prevention following transient ischemic attack.
Topics: Angioplasty, Balloon; Aspirin; Carotid Artery Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2008 |
Re: Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line, Transformed; Dipyridam | 2008 |
The ECV-304 cell-line: should it be used?
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line; Dipyridamole; Endothel | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Prescrip | 2008 |
Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection.
Topics: Animals; Cerebrovascular Circulation; Dipyridamole; Drug Synergism; Hydroxymethylglutaryl-CoA Reduct | 2008 |
From the Food and Drug Administration.
Topics: Aspirin; Dipyridamole; Drug Combinations; Equipment Reuse; Humans; Platelet Aggregation Inhibitors; | 2000 |
FDA approves new drug to reduce risk of stroke.
Topics: Aspirin; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Stroke; United St | 2000 |
Aspirin and dipyridamole for stroke prevention.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stroke | 2000 |
Aggrenox: a combination of antiplatelet drugs for stroke prevention.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Dipyridamole; Dose-Respon | 2000 |
Ischemic heart disease in black South African stroke patients.
Topics: Adult; Aged; Aged, 80 and over; Black People; Chest Pain; Comorbidity; Diabetes Mellitus; Dipyridamo | 2000 |
Outcome in patients with symptomatic occlusion of the internal carotid artery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; | 2000 |
Dipyridamole plus aspirin in cerebrovascular disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebrovascular Disorders; Clinical Trials as Topic | 2000 |
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2000 |
Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
Topics: Anticoagulants; Arrhythmia, Sinus; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Dipyridamole | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
[Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline 'Stroke'].
Topics: Age Factors; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Costs; Health Care Cost | 2000 |
[Old and new platelet aggregation inhibitors: which to choose for prevention of stroke?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2000 |
Transient ischemic attacks after dipyridamole-aspirin therapy.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug The | 2000 |
Aggrenox and stress testing.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; | 2001 |
Newer antiplatelet therapies in stroke prevention.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2001 |
Second stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Chemoprevention; Dipyridamole; Drug Approval; Drug | 2000 |
Clinical correlates and drug treatment of residents with stroke in long-term care.
Topics: Aged; Aged, 80 and over; Aspirin; Cognition Disorders; Comorbidity; Cross-Sectional Studies; Databas | 2001 |
Moyamoya syndrome with spherocytosis: effect of splenectomy on strokes.
Topics: Aspirin; Brain; Child, Preschool; Dipyridamole; Humans; Magnetic Resonance Angiography; Magnetic Res | 2001 |
Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells.
Topics: Cells, Cultured; Dipyridamole; Endothelium, Vascular; Humans; Intracranial Thrombosis; Platelet Aggr | 2001 |
Antithrombotic drugs for secondary stroke prophylaxis--a comment.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Fibri | 2001 |
Antiplatelet therapy: a neurology perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Neurology; Platelet Aggregatio | 2000 |
Antiplatelet therapy: a neurology perspective.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Neurology; Platelet Aggregatio | 2000 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |
Is acetylsalicylic acid plus dipyridamole superior to ASA alone for secondary prevention of stroke?
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Humans; Male; Platelet Aggregation I | 2001 |